-
2023-507878-41-00
4
2025-04-25
Acute myeloid leukemia
-
2024-513862-20-00
5
2025-03-26
Chronic Rhinosinusitis with Nasal Polyposis
-
2023-504925-38-00
4
2024-12-10
patients with hormone receptor (HR)-positive, HER2-negative locally ad
-
2024-512279-10-00
5
2024-11-25
Triple Negative Breast Cancer
-
2023-509706-30-00
5
2024-10-18
Heart failure (HF)
-
2023-508817-18-00
5
2024-10-08
Perennial Allergic Rhinitis (PAR)
-
2022-502559-69-01
4
2024-07-04
advanced (FIGO stage IIIA, IIIB, IIIC, or IV of the 2014 FIGO classifi
-
2023-507407-59-00
5
2024-07-04
Chronic Obstructive Pulmonary Disease (COPD)
-
2024-515267-59-00
4
2024-04-07
Acute myeloid leukemia
-
2023-504031-41-00
5
2024-03-25
ER+/HER2- Early Breast Cancer
-
2024-511219-78-00
5
2023-02-28
epithelial ovarian cancer
-
2023-508389-13-00
5
2022-11-08
Combined endpoint of all-cause mortality, kidney failure, and hospital
-
2022-500764-35-00
6
2022-10-13
Patients with advanced HER2-negative, hormone receptor positive (HER2n
-
2023-504660-41-00
4
2022-07-11
Cholestatic Pruritus in Patients with Primary Biliary Cholangitis (PBC
-
2024-512953-26-00
5
2021-07-06
intermediate-stage hepatocellular carcinoma
-
2024-514014-13-00
9
2020-09-02
female and male adult patients with acute myeloid leukemia
-
2024-512104-19-00
6
2019-11-19
Irritable Bowel Syndrome
-
2024-516814-39-00
5
2025-05-20
Chronic rhinosinusitis with nasal polyps
-
2023-506842-22-00
7
2025-05-19
Recurrent endometrial cancer, recurrent epithelial ovarian, fallopian
-
2023-508932-68-00
4
2024-11-14
Diabetic Peripheral Neuropathic Pain
-
2023-505435-12-00
5
2024-06-04
Asthma
-
2023-507333-17-00
5
2024-04-15
HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
-
2023-506029-12-00
5
2024-04-03
Migraine
-
2022-501024-20-00
5
2023-07-25
ER+/HER2- Early Breast Cancer